VERU is down -12%. Find out why the stock fell today.

Veru Inc (VERU) is trading -12% lower at $12.62 today. The stock's price action is wavering behind it's peers on what is quickly becoming a mildly bearish day for the Consumer Staples sector.

1) Valeo has signed a contract with Veru for the development and commercialization of their COVID-19 drug, sabizabulin.

2) The FDA Advisory Committee will review the emergency use authorization for sabizabulin on a date yet to be announced.

3) Sabizabulin is being developed as a treatment for hospitalized COVID-19 patients who are at high risk for developing acute respiratory distress syndrome (ARDS).

Veru Inc has been trading between a 52-week high of $24.55 and a 52-week low of $4.34. The stock has a market cap of $1.01 Billion.

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate.

As you can imagine, the internet had a few things to say about the price move. Here's a few choice comments from the Reddit Traderverse™:

Odd-Speech-7210 - 3 upvotes - source
VERU - [6 Oct AdCom meeting on Sabi EUA](https://ir.verupharma.com/news-events/press-releases/detail/158/veru-announces-date-for-fda-advisory-committee-meeting-to) and recent [CSA signed with Valeo Pharma](https://valeopharma.com/valeo-pharma-enters-into-canadian-commercial-services-agreement-with-veru-for-sabizabulin-in-hospitalized-adult-patients-with-covid-19-at-high-risk-for-acute-respiratory-distress-syndrome-ards/).

blinddog81 - 1 upvotes - source
CSPs on VERU buddy. Collect that juicy premium boys. Wheel and deal bros.